2011
DOI: 10.1111/j.1399-3038.2010.01096.x
|View full text |Cite
|
Sign up to set email alerts
|

Allergic disease in infants up to 2 years of age in relation to plasma omega‐3 fatty acids and maternal fish oil supplementation in pregnancy and lactation

Abstract: , Allergic disease in infants up to 2 yr of age in relation to plasma omega-3 fatty acids and maternal fish oil supplementation inpregnancy and lactation, 2011, Pediatric Allergy and Immunology, (22) Pediatr Allergy Immunol. AbstractBackground: We have previously reported a protective effect of maternal omega-3 long chain

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

5
194
2
7

Year Published

2013
2013
2018
2018

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 141 publications
(208 citation statements)
references
References 31 publications
5
194
2
7
Order By: Relevance
“…The overall incidence of IgEassociated disease at 6 years of age was higher than that reported in this cohort of children at 1 and 3 years of age 17,18 and other RCTs of prenatal n-3 LCPUFA supplementation for children at high hereditary risk of allergy 7,8,20 . This increased incidence is most likely due to the advancing age of the child when assessed and atopic march progression.…”
contrasting
confidence: 71%
See 1 more Smart Citation
“…The overall incidence of IgEassociated disease at 6 years of age was higher than that reported in this cohort of children at 1 and 3 years of age 17,18 and other RCTs of prenatal n-3 LCPUFA supplementation for children at high hereditary risk of allergy 7,8,20 . This increased incidence is most likely due to the advancing age of the child when assessed and atopic march progression.…”
contrasting
confidence: 71%
“…15 Randomized controlled trials (RCTs) of n-3 LCPUFA supplementation during pregnancy have reported protective effects; however, apart from 1 16-year registry based follow-up, 16 all reported allergic disease outcomes are in early childhood (between 1 and 3 years of age). 7,8,[17][18][19][20] In addition, the small sample size of a number of RCTs 7,8,19,20 introduces bias and a degree of uncertainty regarding results. A recent systematic review evaluating the overall body of literature on the effects of n-3 LCPUFA intake during pregnancy concludes that further evidence from well-powered, high-quality trials are essential to establish benefits.…”
mentioning
confidence: 99%
“…В другом рандомизированном кон-тролируемом исследовании было показано, что даже такая небольшая дотация -3 ДПНЖК, как дополнитель-ный прием к основному рациону беременной женщины (с 20-й нед беременности и до родов) всего двух пор-ций лосося в нед (дотация -3 ПНЖК составляла около 3,45 г ЭПК и ДГК), статистически значимо меняла пока-затели иммунного ответа ребенка (цитокиновый про-филь пуповинной крови). Авторы не обнаружили досто-верной разницы между группами по общему уровню иммуноглобулина (Ig) E и частоте тяжелого атопического дерматита [52]. Однако, в другом рандомизированном исследовании, в котором беременные женщины из груп-пы риска получали 1,6 г ЭПК и 1,1 г ДГК или плацебо с 25-й нед беременности и до 3,5 мес в период лактации, был доказан их протективный эффект в отношении IgE-опосредованных аллергических заболеваний у детей до двухлетнего возраста.…”
Section: педиатрическая фармакологияunclassified
“…The few studies specifically addressing the preventive effect of n-3 PUFA supplementation of pregnant women on children at risk of food allergies, summarized in table 2, have not yet confirmed their beneficial role as a strategy for the primary prevention of food allergy [54][55][56][57][58].…”
Section: Clinical Studiesmentioning
confidence: 99%